Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Mar;131(3):E957-E960.
doi: 10.1002/lary.28873. Epub 2020 Jun 30.

Chloroquine, Hydroxychloroquine and Hearing Loss: A Study in Systemic Lupus Erythematosus Patients

Jose F Polanski  1 , Eloise A Tanaka  2 , Harymy Barros  2 , Adriana G Chuchene  3 , Patricia T G Miguel  3 , Thelma L Skare  2
Affiliations
Observational Study

Chloroquine, Hydroxychloroquine and Hearing Loss: A Study in Systemic Lupus Erythematosus Patients

Jose F Polanski et al. Laryngoscope. 2021 Mar.

Abstract

Objectives/hypothesis: Antimalarial drugs (chloroquine and hydroxychloroquine) are widely used for the treatment of systemic lupus erythematosus (SLE). However, these drugs may have side effects such as hearing loss. This study aimed to describe the hearing function in SLE patients using antimalarials. Secondarily, this study aimed to investigate whether SLE causes hearing loss and if there are any serological or clinical aspects of this diseases associated with inner ear damage.

Study design: Cross-sectional study.

Methods: This study included 84 individuals (43 SLE patients and 41 controls) with audiometry and tympanometry tests. Epidemiological, clinical, serological, and treatment profiles of SLE patients were extracted from the charts.

Results: SLE patients had more sensorineural hearing loss than controls (23.2% vs. 0; P = .001). Pure-tone averages in SLE patients using antimalarials and not using antimalarials were similar (8.75 vs. 8.75; P = .63). At 8,000 Hz, antimalarial dug nonusers performed worse than users (10.00 vs. 22.50; P = .03). Tympanometry was normal in all participants. SLE serological and clinical profiles in patients with and without hearing loss were the same (all P = nonsignificant).

Conclusions: There is a high prevalence of hearing loss in SLE that is not affected by antimalarial drug use.

Level of evidence: 3b Laryngoscope, 131:E957-E960, 2021.

Keywords: Chloroquine; antimalarials; hearing loss; inner ear; systemic lupus erythematosus.

PubMed Disclaimer

References

    1. Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 2007;30:297–308. - PMC - PubMed
    1. Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 2020;16:155–166. - PubMed
    1. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial [published online March 20, 2020]. Int J Antimicrob Agents. 10.1016/j.ijantimicag.2020.105949 - DOI - PMC - PubMed
    1. Costedoat‐Chalumeau N, Dunogué B, Morel N, Le Guern V, Guettrot‐Imbert G. Hydroxychloroquine: a multifaceted treatment in lupus. Presse Med 2014;43(pt 2:e167–e180. - PubMed
    1. Floris A, Piga M, Mangoni AA, Bortoluzzi A, Erre GL, Cauli A. Protective effects of hydroxychloroquine against accelerated atherosclerosis in systemic lupus erythematosus. Mediators Inflamm 2018;3424136 eCollection 2018. 10.1155/2018/3424136. - DOI - PMC - PubMed

Publication types